Pembrolizumab Aids Survival With High-Risk Endometrial Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 21, 2024.

By Lori Solomon HealthDay Reporter

MONDAY, Oct. 21, 2024 -- Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in the Journal of Clinical Oncology.

Brian M. Slomovitz, M.D., from Mount Sinai Medical Center in Miami Beach, and colleagues conducted a protocol-prespecified subgroup analysis of patients with mismatch repair-deficient (dMMR) endometrial cancer from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study undergoing surgery with curative intent. The analysis included patients randomly assigned to pembrolizumab 200 mg or placebo (six cycles) plus carboplatin-paclitaxel (four to six cycles) every three weeks, then pembrolizumab 400 mg (141 patients) or placebo (140 patients) every six weeks (six cycles).

The researchers reported that an interim analysis showed DFS favored pembrolizumab (hazard ratio, 0.31), with median DFS not reached in either group. For pembrolizumab and placebo, two-year DFS rates were 92.4 and 80.2 percent, respectively. No new safety signals were reported.

"Preplanned subgroup analysis based on the study’s stratification factors suggests that pembrolizumab plus chemotherapy improves DFS and is clinically relevant for patients with dMMR tumors in the curative-intent setting," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords